NASDAQ:INVA Innoviva Q3 2025 Earnings Results & Report $18.28 -0.12 (-0.63%) As of 09:41 AM Eastern This is a fair market value price provided by Massive. Learn more. Innoviva beat analyst expectations on both earnings and revenue in its Q3 2025 results, released November 5, 2025. The company reported EPS of $1.08 versus the $0.46 consensus estimate, while revenue of $107.80 million topped the $91.31 million estimate by $16.50 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 5, 2025TimeBefore Market OpensConference Call4:00 PM ET Innoviva EPS ResultsActual EPS$1.08Consensus EPS $0.46Beat/MissBeat by +$0.62One Year Ago EPSN/AEPS Beat Rate4 of last 6 quartersInnoviva Revenue ResultsActual Revenue$107.80 millionExpected Revenue$91.31 millionBeat/MissBeat by +$16.50 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K) Innoviva Q3 2025 Earnings FAQ Did Innoviva beat earnings estimates for Q3 2025? Innoviva (NASDAQ:INVA) reported earnings of $1.08 per share for Q3 2025, beating the consensus estimate of $0.46. The report was announced on Wednesday, November 5, 2025. What was Innoviva's revenue for Q3 2025? Innoviva reported revenue of $107.80 million for Q3 2025, against a consensus estimate of $91.31 million. Innoviva Earnings HeadlinesHC Wainwright Issues Positive Forecast for Innoviva EarningsNovember 19 at 1:42 AM | americanbankingnews.comInnoviva gains new overweight at Piper Sandler on diversified strategyNovember 18 at 6:50 PM | msn.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 19 at 1:00 AM | Base Camp Trading (Ad)Innoviva (NASDAQ:INVA) & Teva Pharmaceutical Industries (NYSE:TEVA) Critical ContrastNovember 17 at 3:23 AM | americanbankingnews.comIs Quarterly Loss Altering The Investment Case For Innoviva Stock (INVA)?November 16 at 7:08 PM | finance.yahoo.comHC Wainwright Issues Negative Forecast for Innoviva EarningsNovember 16 at 1:43 AM | americanbankingnews.comSee More Innoviva Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email. Email Address About InnovivaInnoviva (NASDAQ:INVA) is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions. Its portfolio includes products such as Xenleta and Xacduro for certain bacterial infections, Xerava for complicated intra-abdominal infections, and Giapreza for dangerously low blood pressure in adults with septic or other distributive shock. The company was formerly known as Theravance, Inc. and adopted the Innoviva name in 2015, following the separation of Theravance Biopharma. Innoviva’s products and royalty arrangements give it a presence in markets beyond the United States, though the geographic reach varies by product and commercial partner.View Innoviva ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Viking’s Low-Water Miss Looks Like a Buy-the-Dip OpportunityDisney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.